A new research perspective was published in Oncotarget’s Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib
Featured content in this Issue: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists Long-Term Effects of Microdosing Remain Key Unknown; Cardiac
If you’re pregnant, you may want to think twice before making a hamburger run or reaching for a prepackaged pastry, according to research published last
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck CEO Robert Davis, Johnson & Johnson CEO Joaquin Duato, and
Mount Sinai researchers have shown for the first time that immune cells called monocytes, derived in the bone marrow and released into the bloodstream, can
By the numbers Q4 revenue: $1.94 billion 6.3% increase year over year Q4 net income: $419.2 million Compared to a net loss of $130.5 million
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Insulet has received a CE
Aurora Cannabis Acquires MedReleaf Australia Aurora becomes the largest global medical cannabis company operating in nationally legal markets. MedReleaf Australia holds the #2 position in
Immunotherapies using engineered T cells have ushered in a new era in cancer treatment, but they have their limits. They may cause side effects or
Our sense of direction is essential to our ability to navigate the world around us. It acts as the brain’s internal compass to help us